PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...
Search results for - pharmajet
PharmaJet to present immune response DNA vaccine data
Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...
PharmaJet partner seeks EUA in India for needle-free Omicron booster
PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...
PharmaJet partner gets fast track for cancer vaccine
PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...
PharmaJet receives NIH grant for HPV needle-free immunization study
Closely-held PharmaJet received an $800,000-plus direct to Phase 2 grant from the NIH to evaluate the immunogenicity of intradermal administration of human papilloma virus (HPV) vaccine using the company’s Tropis...
PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots
Closely-held PharmaJet received a multi-year, $1.5-million grant from the United States Agency for International Development (USAID) to evaluate the impact of intradermal vaccine administration using the company’s...
PharmaJet partner, Scancell, to use needle-free delivery with melanoma vaccine
PharmaJet partner, Scancell, will include PharmaJet’s needle-free delivery system in a Phase 2 clinical study of a vaccine for treatment of patients with advanced melanoma. Scancell’s immunotherapy platform uses the...
PharmaJet sponsor study published in The Lancet
A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...
PharmaJet presents partner data on immunogenicity with needle-free systems
Closely-held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...
Immunomic Therapeutics to use PharmaJet system in skin cancer trial
Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...
